Hyperdiluted Triamcinolone Injections for Nasal and Alar Contouring

Demand for minimally invasive nasal contour refinement has increased, particularly among patients seeking subtle esthetic improvement without surgery or volume augmentation. While hyaluronic acid filler-based nonsurgical rhinoplasty can alter contour, it fundamentally adds volume and carries rare but severe vascular risks. In contrast, intralesional corticosteroids are known to induce localized soft-tissue thinning and have been used in postoperative rhinoplasty to manage supratip fullness, suggesting a potential role in nonsurgical soft-tissue contour modulation.

To describe a nonsurgical, nonfiller technique using hyperdiluted triamcinolone acetonide (TAC) microinjections for targeted reduction of nasal and alar soft-tissue fullness, and to present a structured case-series protocol with standardized Global Aesthetic Improvement Scale (GAIS) reporting.

Twenty adult patients underwent a standardized 10-point microinjection protocol using hyperdiluted TAC (approximately 1.3 mg/mL), with 1.0 mL administered per session and sessions repeated every 3 weeks for a total of five sessions. The cumulative TAC dose per patient was approximately 6.5 mg. Outcomes were assessed using patient-reported GAIS at final follow-up. This manuscript provides a patient-level GAIS reporting framework and an illustrative results table to support transparent outcome documentation. The technique is conceptually distinct from surgical rhinoplasty and filler-based approaches, aiming for gradual, localized soft-tissue thinning through dose-minimized, distributed corticosteroid exposure.